Stocks Health care CTXR
NASDAQ · Health careCitius Pharmaceuticals, Inc. (CTXR)
It posted a net loss of $45.2M. At June 30, 2026 it held $17M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Key facts about Citius Pharmaceuticals, Inc.
- Net worth
- Citius Pharmaceuticals, Inc. has a market value (market cap) of $13.2M at the latest share price, and shareholders' equity of $66.6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2022 revenue was $90K (0.0% year on year), with a net loss of $33.6M.
- Cash flow
- In fiscal 2025 operations used $26.6M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 14, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Citius Pharmaceuticals, Inc.'s next report is expected around December 22, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
- Dividend
- Citius Pharmaceuticals, Inc. paid dividends of $0.60 per share in fiscal 2016.
What Citius Pharmaceuticals, Inc. does
Citius Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CTXR.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$37.4M | -$3.38 | n/a |
| 2024 | n/a | -$40.2M | -$5.97 | n/a |
| 2023 | n/a | -$32.5M | -$5.57 | n/a |
| 2022 | $90K | -$33.6M | -$0.23 | n/a |
| 2021 | $90K | -$23.1M | -$0.23 | -$24.3M |
| 2020 | $90K | -$17.5M | -$0.45 | -$16.9M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Dividends
Citius Pharmaceuticals, Inc. paid $0.60 per share in fiscal 2016.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2016 | $0.60 | n/a | n/a |
Latest SEC filings
What Citius Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 21, 2026
- August 14, 2026
- August 14, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 5, 2026Other event 8-K
- June 1, 2026Other event 8-K
- May 22, 2026
- May 15, 2026
- May 15, 2026Quarterly report 10-Q · period to March 31, 2026Revenue was $1.7M; diluted EPS -$0.95 versus -$1.27.
- May 8, 2026
Insider trades
What the people running Citius Pharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns CTXR
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| CVI Investments, Inc.13G, passive with 1 related filers | 9.9% | August 14, 2026 |
Largest institutional holders
Insiders
Questions about CTXR
What does Citius Pharmaceuticals, Inc. do?
Citius Pharmaceuticals, Inc. is a company in the Health care sector, listed on NASDAQ as CTXR. Its shares trade on NASDAQ under the ticker CTXR.
What is Citius Pharmaceuticals, Inc.'s net worth?
Citius Pharmaceuticals, Inc. has a market value (market cap) of $13.2M at the latest share price, and shareholders' equity of $66.6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Citius Pharmaceuticals, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $45.2M.
When did Citius Pharmaceuticals, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the stock exchange listing notice from August 21, 2026.
When is Citius Pharmaceuticals, Inc.'s next earnings report?
Citius Pharmaceuticals, Inc.'s next report is expected around December 22, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Does Citius Pharmaceuticals, Inc. pay a dividend?
Yes. Citius Pharmaceuticals, Inc. paid dividends of $0.60 per share in fiscal 2016.
Similar companies
Compare CTXR with
Follow CTXR
Get an email when Citius Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Citius Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.